Fintel reports that on September 18, 2023, Cantor Fitzgerald reiterated coverage of MoonLake Immunotherapeutics - (NASDAQ:MLTX) with a Overweight recommendation.
Analyst Price Forecast Suggests 9.70% Upside
As of August 31, 2023, the average one-year price target for MoonLake Immunotherapeutics - is 63.24. The forecasts range from a low of 32.32 to a high of $90.30. The average price target represents an increase of 9.70% from its latest reported closing price of 57.65.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for MoonLake Immunotherapeutics - is 0MM. The projected annual non-GAAP EPS is -1.51.
What is the Fund Sentiment?
There are 142 funds or institutions reporting positions in MoonLake Immunotherapeutics -. This is an increase of 75 owner(s) or 111.94% in the last quarter. Average portfolio weight of all funds dedicated to MLTX is 0.81%, an increase of 42.54%. Total shares owned by institutions increased in the last three months by 41.93% to 56,057K shares. 
The put/call ratio of MLTX is 5.89, indicating a bearish outlook.
What are Other Shareholders Doing?
Bvf holds 21,751K shares representing 40.67% ownership of the company. No change in the last quarter.
Cormorant Asset Management holds 8,142K shares representing 15.22% ownership of the company. In it's prior filing, the firm reported owning 6,892K shares, representing an increase of 15.35%. The firm increased its portfolio allocation in MLTX by 139.59% over the last quarter.
Citadel Advisors holds 2,021K shares representing 3.78% ownership of the company. In it's prior filing, the firm reported owning 2,923K shares, representing a decrease of 44.68%. The firm increased its portfolio allocation in MLTX by 54.90% over the last quarter.
Price T Rowe Associates holds 1,943K shares representing 3.63% ownership of the company. In it's prior filing, the firm reported owning 831K shares, representing an increase of 57.24%. The firm increased its portfolio allocation in MLTX by 1,070.86% over the last quarter.
Avoro Capital Advisors holds 1,725K shares representing 3.23% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
